Meredith Culp

Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

L. Schneider, D. Bennett, Y. Stern, 2021, The Journal of Prevention of Alzheimer's Disease.

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Jennifer G. Robinson, Alex A. Knopman, D. Rujescu, 2021, The Lancet Neurology.

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial

L. Schneider, C. Lyketsos, A. Monsch, 2019, Alzheimer's & dementia.

TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM

K. Welsh-Bohmer, A. Saunders, J. Burke, 2019, Alzheimer's & Dementia.